Core Viewpoint - Long Fung Group Holdings Limited, a well-known drugstore chain in Hong Kong, has submitted its application for an IPO on the Hong Kong Stock Exchange, raising questions about whether this is a chance for value reassessment or a high-leverage gamble given the current market conditions [1] Financial Performance - Long Fung Group is projected to achieve a revenue increase from HKD 1.094 billion to HKD 2.460 billion from fiscal year 2023 to 2025, with a compound annual growth rate (CAGR) of 50% [3] - Gross profit margin is expected to rise from 24.9% to 31.6% during the same period, with net profit turning positive at HKD 145 million in fiscal year 2024 and increasing to HKD 170 million in fiscal year 2025 [3] - In the first quarter of fiscal year 2026, profits surged by 130.7% year-on-year, indicating strong growth momentum [3] Market Position - Long Fung Group holds a 5.2% market share, making it the largest pharmaceutical retailer in Hong Kong, and has the highest average SKU count per store at approximately 6,500 [3] - The flagship store in Mong Kok, spanning 17,500 square feet, exemplifies its "supermarket-style drugstore" model, combining pharmaceuticals, beauty products, and daily necessities [3] Financial Structure and Risks - As of June 30, 2025, Long Fung Group's net current liabilities reached HKD 332 million, with short-term borrowings of HKD 625 million and cash equivalents of only HKD 33.6 million, indicating a reliance on supplier credit and bank financing [4] - The company has a staggering debt-to-asset ratio of 809.4%, with negative net assets, as nearly all assets are mortgaged for financing [4] - Revenue is heavily dependent on the Hong Kong market, with 97.2% coming from physical stores concentrated in tourist areas, making it vulnerable to fluctuations in tourist traffic [4] Online Presence and Competition - Online revenue for fiscal year 2025 is projected at only HKD 43 million, accounting for 1.7% of total revenue, and has been declining for three consecutive years [5] - The company’s online strategy lacks effective user engagement, contrasting sharply with competitors like Watsons and Mannings [5] Governance and Management Concerns - The governance structure raises concerns, with the family of the founder holding 100% control through TTK Holding, leading to frequent related-party transactions [5] - As of 2025, receivables from related parties amounted to HKD 289 million, nearly 40% of current assets, and significant dividends were paid to core subsidiaries before the IPO [5] Growth Drivers - The recovery of tourism spending post-2023 and the expansion from 13 to 29 stores are key growth factors, along with an increase in proprietary brand sales to 13.6%, enhancing overall gross margins [6] Competitive Advantages - Long Fung Group benefits from a deep understanding of local consumer culture, a vast SKU assortment, a professional team of pharmacists and beauty consultants, and a procurement office in Japan, creating competitive barriers [7] Future Expansion Challenges - The company plans to open up to 11 new stores by 2029, but faces challenges due to rising vacancy rates and high rental costs in Hong Kong [8] - Same-store sales growth has dropped from 64% to 5.6%, indicating diminishing returns on expansion efforts [8] - The potential for growth in the Greater Bay Area remains unproven, raising questions about the sustainability of its "drugstore king" title beyond Hong Kong [8]

Core Viewpoint - Mannings, a drugstore chain, announced the closure of all its offline stores and online mall in mainland China, with the last operating day for physical stores set for January 15, 2026, and the online store ceasing operations on December 28, 2025 [1][3]. Group 1: Company Performance - Mannings entered the mainland China market in 2004 and has over 120 stores in the region, but has struggled to replicate its successful business model from Hong Kong due to regulatory constraints and market differences [3][12]. - The company’s brand image in mainland China is unclear, lacking the professional authority of a pharmacy and the trendy appeal of a modern retail store [3][12]. - Other Hong Kong brands, such as Sa Sa International, have also exited the mainland market, while Watsons continues to explore options despite a 3% revenue decline and a 53% drop in profit in the first half of the year [3][5]. Group 2: Market Environment - The retail landscape in mainland China has shifted dramatically, with local brands rising and e-commerce platforms like Alibaba and JD.com changing consumer shopping habits [12]. - Traditional Hong Kong retail brands, including Mannings, have struggled to adapt to the competitive environment, often relying on outdated operational models that do not resonate with local consumers [12]. - High operational costs, including rent and labor, have further pressured profit margins for these brands, as they often choose locations in prime areas with high rental costs [12]. Group 3: Industry Trends - The trend of closing physical stores is not isolated to Mannings; other brands like AEON and Taste are also reducing their presence in mainland China due to declining performance [6][12]. - The overall market for Hong Kong retail brands is challenging, with many facing significant revenue declines and increased competition from local and online retailers [10][12]. - Experts suggest that for Hong Kong retail brands to succeed in mainland China, they need to adopt strategies such as developing O2O models, optimizing product offerings, and focusing on core urban areas [12].

Core Viewpoint - Longfeng Group is seeking to become the first "cosmetic retail stock" in Hong Kong by submitting an IPO application, but faces challenges due to its reliance on physical stores, tight financial conditions, and concentrated family governance structure [1]. Group 1: Business Model and Growth - Longfeng Group operates 29 physical retail stores in Hong Kong as of June 30, 2025, with 97.2% of its revenue coming from these stores, while online sales contribute only 1.7% [2]. - The company's revenue grew from HKD 1.094 billion to HKD 2.460 billion from FY2023 to FY2025, with a compound annual growth rate (CAGR) of 50% [3]. - The number of stores increased from 16 in FY2023 to 29 in FY2025, but same-store sales growth dropped from 64% in FY2024 to 5.6% in FY2025, indicating a negative impact on existing stores from new openings [3]. Group 2: Financial Performance - The gross profit margin improved from 24.9% in FY2023 to 31.9% in Q1 FY2026, driven by an increase in high-margin beauty product sales, which rose from 28.0% of revenue in FY2023 to 33.3% in FY2025 [3]. - Despite a high gross margin, the net profit margin decreased from 7.2% in FY2024 to 6.9% in FY2025, which is below the industry leader Watsons' margin of 8%-10% [3]. - As of June 30, 2025, the company had a net current liability of HKD 331.6 million and short-term borrowings of HKD 625 million, with cash and cash equivalents at only HKD 33.6 million, indicating a significant debt repayment gap [3]. Group 3: Governance and Market Position - Longfeng Group is a family-controlled business, with 100% ownership by the founder's family, raising concerns about transparency and fairness in related party transactions [5]. - The company paid HKD 13.65 million in rent for five stores leased from the controlling shareholder, which accounted for 9.8% of total rental expenses, but lacks detailed third-party valuation disclosures [5]. - As a business heavily reliant on the Hong Kong market, which accounts for over 97% of its revenue, Longfeng Group's performance is closely tied to local economic cycles, consumer confidence, and tourist traffic [5].

Core Viewpoint - Long Fung Group, Hong Kong's largest drugstore retailer, has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, potentially becoming the first local drugstore retail stock. However, its rapid growth is overshadowed by risks such as reliance on offline channels, high current liabilities, and family governance issues [1][9]. Financial Performance - Long Fung Group's revenue growth is remarkable, with income rising from HKD 1.094 billion to HKD 2.460 billion from FY2023 to FY2025, reflecting a compound annual growth rate (CAGR) of 50%. In Q1 FY2026, revenue increased by 42.5% year-on-year, and net profit surged by 130.7%. However, the sustainability of this profit structure is questionable, as the company reported a loss of HKD 27.14 million in FY2023, and while it turned profitable in FY2024, the net profit margin fell from 7.2% to 6.9%, below competitors like Watsons [2][10]. - As of June 30, 2025, the company had a net current liability of HKD 332 million and short-term borrowings of HKD 625 million, with cash and cash equivalents at only HKD 33.608 million, indicating a significant debt repayment gap. The interest coverage ratio stands at 6.5 times, and rising financing costs during Hong Kong's interest rate hike cycle may further squeeze profit margins [2][10]. Business Model and Supply Chain Risks - The business model of Long Fung Group is heavily reliant on offline channels, with 97.2% of revenue coming from physical stores and only 1.7% from online sales, which have declined from HKD 44.637 million in FY2023 to HKD 42.682 million in FY2025. This contrasts sharply with the average online penetration rate of over 20% in Hong Kong's retail sector, highlighting a lag in digital transformation [3][11]. - Over 50% of the company's procurement relies on parallel import channels, which can reduce costs by 10-15% but also exposes the company to compliance risks regarding product labeling. Long Fung has previously received warnings from customs for labeling issues, and tighter regulations or lawsuits from brand owners could disrupt supply chain stability [3][11]. Governance and Related Party Transactions - Long Fung Group has a highly concentrated ownership structure, with the Tse family holding 100% of shares through TTK Holding, leading to a family-controlled board. While this governance model allows for efficient decision-making, the lack of checks and balances may pose risks [4][12]. - As of June 30, 2025, receivables from related parties amounted to HKD 289 million, representing 39.33% of current assets, raising concerns about potential fund occupation risks [4][12]. Operational Compliance and Competitive Pressure - The company has aggressively expanded its store count from 13 to 29 in recent years, but same-store sales growth has plummeted from 64% to 5.6%, indicating a cannibalization effect between new and existing stores. Additionally, several stores have faced regulatory warnings for building or usage violations [5][13]. - The competitive landscape is intensifying, with the Hong Kong drugstore retail sector growing at only 6.2%, while Long Fung's growth rate is at 21.1%, significantly above the industry average. However, with competitors like Watsons and Mannings ramping up promotions, the sustainability of this growth is in question. Inventory turnover days have increased to 68 days, raising the risk of inventory impairment if consumer demand falls short [5][13][14]. Industry Context and Future Opportunities - Long Fung's rise coincides with a reshuffling period in Hong Kong's drugstore industry, where former leaders like Sa Sa and Bonjour have lost their luster, while Watsons and Mannings continue to expand. Long Fung aims to balance local customer needs and tourist demand with its strategy of "reputation from pharmaceuticals, profit from beauty," but its dependence on tourism remains a vulnerability [6][15]. - The IPO fundraising plan is intended for store expansion, IT system upgrades, and supply chain optimization. The company urgently needs capital to alleviate financial pressures, but investors should scrutinize three key transformation areas: breaking into online channels, regional expansion, and modernizing governance. The ability to convert 30 years of brand trust into sustainable competitive advantage will determine the reshaping of Hong Kong's drugstore industry [6][15]. Conclusion - Long Fung Group's IPO represents a significant test for the valuation of local retail brands in Hong Kong. Its supply chain resources, local customer trust, and product category advantages form a competitive moat, but risks related to financial leverage, governance structure, and channel singularity cannot be overlooked. The company's path to capitalization will not only test its business model but also serve as a window into the resilience of Hong Kong's economy [8][16].

Core Viewpoint - Long Fung Group Holdings Limited, based in Hong Kong, has submitted a prospectus to the Hong Kong Stock Exchange for a main board listing, positioning itself as a leading retail pharmacy and drugstore operator in Hong Kong with a significant market share in the sector [1] Group 1: Company Overview - Long Fung Group operates under the "Long Fung" brand with 29 retail stores and various online sales platforms, offering a wide range of drugstore products and consumer goods [1] - The company is projected to be the largest pharmacy retailer in Hong Kong by retail sales in 2024, holding a market share of 5.2%, and is also the largest drugstore retailer by average SKU per store, with approximately 6,500 SKUs available [1] - The flagship store located in Mong Kok has a total floor area of about 17,500 square feet, making it the largest drugstore retail store in Hong Kong by floor area in 2024 [1] Group 2: Product Offering and Supplier Relationships - Long Fung Group's product range includes 11 categories such as traditional Chinese medicine, Western medicine, health supplements, skincare, cosmetics, personal care, baby products, food, pet food, and household items, with over 46,000 product SKUs sold during the reporting period [2] - The company collaborates with over 600 suppliers, including local distributors in Hong Kong and major overseas suppliers from Japan, South Korea, Southeast Asia, Europe, and the United States, with a supply chain office established in Fukuoka, Japan [2] - Long Fung Group maintains long-term partnerships with well-known brands, being the largest purchaser of certain products like infant formula from Meiji and specific cold medicine products from Heping Pharmaceutical in Hong Kong [2] Group 3: Financial Performance and Growth - For the fiscal years 2023 to 2025, Long Fung Group's total revenue is projected to be HKD 1.094 billion, HKD 2.021 billion, and HKD 2.461 billion, respectively, reflecting a strong compound annual growth rate (CAGR) of 50.0% over three years [3] - In contrast, the CAGR for Hong Kong's consumer goods retail sales from 2020 to 2024 is only 3.6%, indicating that Long Fung Group significantly outperforms the market [3] - The net profit is expected to increase from approximately HKD 145 million in the fiscal year 2024 to about HKD 170 million in the fiscal year 2025, representing a growth of 17.9% [3] Group 4: IPO Fund Utilization - The funds raised from the IPO are intended for expanding and optimizing the company's physical and online sales networks, enhancing supply chain capabilities through the expansion of overseas procurement offices in Japan and South Korea, and upgrading IT systems including warehouse management and point-of-sale systems [3] - The company also plans to seek selective strategic investments and acquisition opportunities to further develop its business scale and geographic coverage [3]

Core Viewpoint - Lung Fung Group Holdings Limited has submitted an application for listing on the Hong Kong Stock Exchange, with DBS acting as the sole sponsor. The company is a leading retail pharmacy and cosmetics operator in Hong Kong, aiming to expand its market presence and product offerings. Group 1: Company Overview - Lung Fung operates under the "Lung Fung" brand and is the largest pharmacy retailer in Hong Kong by retail sales, holding a market share of 5.2% as of 2024 [3] - The company has 29 retail stores in Hong Kong and various online sales platforms, providing a wide range of products [3][4] - Lung Fung's flagship store in Mong Kok is the largest cosmetics retail store in Hong Kong by total floor area, measuring approximately 17,500 square feet [3] Group 2: Product Range and Supply Chain - The company offers a diverse range of products across 11 categories, including traditional Chinese medicine, Western medicine, health supplements, skincare, cosmetics, and pet products [4] - Lung Fung has established over 40 private label brands and offers more than 700 SKUs under these brands as of Q1 2026 [5] - The company sources products from over 600 suppliers globally, including local distributors and major suppliers from Japan, Korea, Southeast Asia, Europe, and the United States [5] Group 3: Financial Performance - Lung Fung's revenue grew significantly from HKD 1.094 billion in FY2023 to HKD 2.461 billion in FY2025, with a compound annual growth rate (CAGR) of 50.0% [8] - The company recorded a net profit of HKD 145 million in FY2024, with a net profit margin of 7.2%, and further increased to HKD 170 million in FY2025 [8] - For Q1 FY2026, the profit reached HKD 47.8 million, a 130.7% increase from Q1 FY2025, with a profit margin of 6.8% [9] Group 4: IPO Fund Utilization - The funds raised from the IPO are intended for expanding and optimizing both physical and online sales networks, including opening up to 11 new retail stores in Hong Kong by March 31, 2029 [9][10] - The company plans to invest in brand management and marketing to enhance public awareness and effectiveness of promotional activities [9] - Additional funds will be allocated for upgrading IT systems, enhancing supply chain capabilities, and seeking strategic investment opportunities [10]

Group 1 - Long Feng Group has submitted a listing application to the Hong Kong Stock Exchange, with DBS Bank as the sole sponsor [1] - The company operates under the "Long Feng" brand and is a leading retail pharmacy and cosmetics operator in Hong Kong [1] - According to a Frost & Sullivan report, Long Feng Group is the largest retail pharmacy in Hong Kong by retail sales, holding a market share of 5.2% in 2024 [1] Group 2 - Long Feng Group is also the largest cosmetics retailer in Hong Kong by average store SKU, offering approximately 6,500 SKUs per store [1] - As of the last practicable date, the company operates 29 retail stores and various online sales platforms in Hong Kong [1] - The flagship store located in Mong Kok's家乐坊 has a total floor area of approximately 17,500 square feet, making it the largest cosmetics retail store in Hong Kong in 2024 [1]

Core Viewpoint - Long Fung Group Holdings Limited has submitted its main board listing application to the Hong Kong Stock Exchange, aiming to leverage its market position as the largest pharmaceutical retailer in Hong Kong by 2024 with a market share of 5.2% [1] Business Layout - Long Fung Group operates a network of 29 retail stores across Hong Kong, strategically located with 5 on Hong Kong Island, 10 in Kowloon, and 14 in the New Territories, primarily in street shop formats [3] - The flagship store in Mong Kok, with a total area of approximately 17,500 square feet, is projected to be the largest drugstore in Hong Kong by 2024, while the average store size is 4,254 square feet [3] - The company utilizes multiple online channels, including its official website and platforms like Tmall and JD.com, creating an omnichannel retail matrix [3] - The product range includes 11 categories such as traditional Chinese medicine, Western medicine, health supplements, and beauty products, with over 46,000 SKUs sold during the reporting period [3] Financial Performance - Revenue is projected to grow from HKD 1.094 billion in the 2023 fiscal year to HKD 2.461 billion in the 2025 fiscal year, reflecting a compound annual growth rate (CAGR) of 50% [4] - Gross margin is expected to increase from 24.9% to 31.6% over the same period [4] - The company recorded a loss of HKD 27.1 million in the 2023 fiscal year but is forecasted to achieve a net profit of HKD 145 million in 2024 and further increase to HKD 170 million in 2025 [4] - In the first quarter of the 2026 fiscal year, revenue reached HKD 697 million, a year-on-year increase of 42.5%, with net profit soaring by 130.7% to HKD 47.8 million [4] Use of IPO Proceeds - The IPO proceeds are intended for various purposes, including opening up to 11 new stores in Hong Kong by 2029, inventory procurement, employee training, and enhancing brand marketing through celebrity endorsements [5] - Additional plans include upgrading procurement offices in Japan and South Korea, improving IT systems, repaying loans, and seeking strategic investment opportunities [5]

Core Viewpoint - Long Fung Group Holdings Limited, Hong Kong's largest drugstore retailer, has submitted its main board listing application to the Hong Kong Stock Exchange, with DBS Asia Capital as the sole sponsor [3]. Financial Performance - Long Fung Group's revenue is projected to grow from approximately HKD 1.094 billion in FY2023 to about HKD 2.461 billion in FY2025, reflecting a compound annual growth rate (CAGR) of 50.0%, significantly outpacing the Hong Kong retail sector's CAGR of 3.6% from 2020 to 2024 [4]. - The company's gross profit margins have shown consistent improvement over the past three fiscal years, recorded at 24.9%, 29.3%, and 31.6%, with net profit expected to rise from approximately HKD 145 million in FY2024 to about HKD 170 million in FY2025, marking a 17.9% increase [4]. Market Position and Strategy - Long Fung Group has established a comprehensive retail ecosystem in Hong Kong's health, pharmaceutical, and beauty product market, leveraging a three-dimensional strategy of "brand uniqueness, product diversity, and immersive experience" to surpass traditional drugstore retail models [5]. - The average store size exceeds 4,250 square feet, with the flagship store in Mong Kok being the largest drugstore in Hong Kong at approximately 17,500 square feet, featuring 15 registered pharmacists and over 38 professional beauty consultants [5]. Supply Chain and Management - The company's competitive edge is supported by a flexible supply chain and an experienced management team, with long-term partnerships with key suppliers and a procurement office in Japan to stay aligned with emerging product trends [6]. - The founder, Mr. Hsieh Shao-Hai, has over 35 years of experience in the Hong Kong retail drugstore industry, and the core team includes talents from internationally renowned retail groups, combining global perspectives with local consumer insights [6].

Core Viewpoint - Long Fung Group, a leading retail pharmacy in Hong Kong, is experiencing rapid revenue growth but faces significant risks due to its heavy reliance on offline sales channels and various operational challenges [1][2][12] Business Overview - Long Fung Group operates 29 physical stores and an online platform, with a product range that includes traditional Chinese medicine, Western medicine, health products, and cosmetics, totaling over 46,000 SKUs [1] - The company holds a 5.2% market share in the pharmacy sector and a 5.8% share in the cosmetics retail sector, making it the largest pharmacy retailer in Hong Kong [1] Revenue Growth - Revenue increased from HKD 1.094 billion in FY2023 to HKD 2.460 billion in FY2025, achieving a compound annual growth rate (CAGR) of 50% [2] - The first quarter of FY2026 saw revenue of HKD 697.4 million, maintaining a year-on-year growth rate of 42.5% [2] - The growth is primarily driven by the expansion of physical stores, with 13 new stores added from FY2023 to FY2025 [2] Profit Performance - Net profit fluctuated significantly, with a loss of HKD 27.14 million in FY2023, turning into a profit of HKD 144.5 million in FY2024, and further increasing to HKD 170.4 million in FY2025 [3] - The first quarter of FY2026 reported a net profit of HKD 47.76 million, a year-on-year increase of 130.7% [3] Gross and Net Margins - Gross margin improved from 24.9% in FY2023 to 31.9% in the first quarter of FY2026, driven by a higher proportion of high-margin products [4] - Despite the increase in gross margin, net margin decreased to 6.9% in FY2025 due to high sales and distribution expenses [4] Revenue Composition - In FY2025, cosmetics accounted for 33.3% of total revenue, followed by pharmaceuticals at 19.2% and health products at 17.6% [5] - The company faces a significant imbalance in its sales channels, with offline sales contributing 97.2% of revenue and online sales only 1.7% [5] Customer and Supplier Dynamics - The customer base is highly diversified, with the top five customers contributing less than 5% of total revenue [6] - However, there is a risk associated with suppliers, as 55.3% of procurement comes from unofficial parallel import channels, which poses compliance risks [6] Shareholding and Governance - The company is predominantly controlled by the Tse family, holding 97.3% of shares, leading to a family-run governance structure [7] - There are concerns regarding the fairness of pricing in related-party transactions, particularly in rental agreements with the controlling shareholder [7] Financial Risks - As of June 30, 2025, the company had a net current liability of HKD 331.6 million and a debt-to-asset ratio of 68% [8] - The reliance on supplier financing for 44.1% of short-term borrowings raises liquidity concerns [8] Operational Risks - There are significant compliance issues with five stores involved in illegal leasing, which could lead to forced relocations [9] - Inventory turnover days increased from 51 days in FY2024 to 61 days in FY2025, indicating declining inventory management efficiency [9] Market Risks - The company is heavily reliant on the Hong Kong market, which contributes over 97% of its revenue, making it vulnerable to local economic fluctuations [10] - The competitive landscape is intensifying, with major players increasing promotional activities, potentially impacting Long Fung's growth sustainability [11]